Bradley S Rosen MD: Rapamycin and Acarbose for Longevity in Practice

Aging is a malleable biological process that can be targeted therapeutically to extend health span and delay the onset of chronic, age-related diseases. Rather than viewing aging as simple, inevitable wear and tear, clinical practice should focus on mitigating risk factors through lifestyle optimization—specifically diet, exercise, and sleep—and the strategic use of pharmacological agents. Dr. Bradley S. Rosen, a physician specializing in biogerontology, highlights how interventions like rapamycin, acarbose, metformin, and SGLT2 inhibitors modulate metabolic pathways such as mTOR and glucose signaling to improve resilience. While randomized controlled trials in humans remain limited, historical clinical data and animal models suggest these therapies can reduce the probability of disabling events. A proactive, evidence-informed approach allows individuals to navigate the transition into later life with greater vitality, prioritizing long-term health outcomes over the passive acceptance of age-related decline.